The Hyderabad based, Suven Life Sciences Limited (Suven) has added more feathers to its cap by winning patent rights for 4 new products, one from Europe (EP 2155674), two from Sri Lanka (14612 and 14838) and one from Korea (1049868) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

The patents rights gained by the company are valid through 2027, 2025 and 2024 respectively. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With the addition of these four new patents, Suven has a total of eleven granted patents from Europe, eight from Srilanka and five granted patents from South Korea. Venkat Jasti, CEO, Suven Life sciences Limited, said, “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena, that are being developed for cognitive disorders which has an estimated market of $ 30 billion globally.

The company said these patents are its exclusive intellectual property, achieved through internal research. Products developed out of these inventions may be out licensed at different phases of clinical development.